Goldman Sachs Group Inc Cardiol Therapeutics Inc. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 35,900 shares of CRDL stock, worth $36,259. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,900
Previous 36,100
0.55%
Holding current value
$36,259
Previous $71,000
35.21%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
7.56MCall Options Held
4.9KPut Options Held
3.8K-
Tejara Capital LTD London, X03.12MShares$3.15 Million2.61% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD882KShares$891,3120.23% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$803,5810.31% of portfolio
-
Pvg Asset Management Corp Golden, CO487KShares$492,1673.54% of portfolio
-
Lion Street Advisors, LLC334KShares$337,0620.11% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $62.6M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...